Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eo-Drive: Eosinophil-driven Corticotherapy for COPD Exacerbation
NCT04234360Phase 3Terminated
- Sponsor
- CHU Montpellier
- Start
- Oct 2021
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisone in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by CHU Montpellier. Primary endpoint: Treatment failure at 3 months. Started Oct 2021; status: terminated.
02
Drugs
prednisone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04234360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234360.